OrthoPediatrics Corp. filings document the regulatory record of a Nasdaq-listed medical device company focused on pediatric orthopedics. Its Form 8-K reports include quarterly and annual results, unaudited financial statements, revenue trends across Trauma and Deformity, Scoliosis, Sports Medicine/Other and OrthoPediatrics Specialty Bracing, as well as management guidance and investor presentation materials furnished under Regulation FD.
The company’s filings also cover governance and ownership matters through proxy statements, including board elections, executive compensation and equity awards. Material-event filings describe financing arrangements such as amendments to credit agreements and delayed draw term loan capacity, tying capital structure disclosures to the company’s operating and liquidity needs.
ORTHOPEDIATRICS CORP (KIDS) insider reporting person David R. Pelizzon, a director and ten percent owner, reported indirect sales of Orthopediatrics common stock carried out by Squadron Capital LLC. Squadron sold a total of 336,831 shares on August 28 and September 1, 2026 at weighted average prices in the low‑$23 range, with prices ranging from $23.00 to about $23.82. Pelizzon is President and a member of Squadron’s Managing Committee and may be deemed a beneficial owner of these indirectly held shares, but he expressly disclaims beneficial ownership except to the extent of his pecuniary interest. He also reports 44,384 shares of common stock held directly, including 17,959 restricted stock awards.
ORTHOPEDIATRICS CORP (KIDS) reported that Jennifer N. Pritzker, a ten percent owner, filed a Form 4 showing indirect sales of an aggregate 38,300 shares of common stock on August 24–26, 2026. The sales were executed by Squadron Capital LLC, a manager-managed LLC, at weighted average prices around the mid-$20s per share, with detailed price ranges disclosed in footnotes. Pritzker reports 10,900 shares held directly and disclaims beneficial ownership of the indirectly held shares except to the extent of her pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) reported insider activity by large shareholder entities Squadron Capital LLC and Squadron Capital Holdings LLC. Squadron Capital LLC sold a total of 38,300 shares of Common Stock over August 24–26, 2026 in open-market transactions at weighted-average prices between about $24.13 and $25.82 per share. The filing states the sales were undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses. The shares are held directly by Squadron Capital LLC, and Squadron Capital Holdings LLC is its controlling member.
ORTHOPEDIATRICS CORP (KIDS) received a Form 4 from director and ten percent owner David R. Pelizzon reporting sales of common stock held indirectly through Squadron Capital LLC. On 2026-08-24, 2026-08-25, and 2026-08-26, Squadron sold a total of 38,300 shares of Orthopediatrics common stock in open-market or private transactions at weighted average prices reported as $25.75, $24.74, and $24.28 per share, each with detailed price ranges provided in footnotes. A separate entry shows Pelizzon holding 44,384 shares directly as of 2026-08-24, including 17,959 restricted stock shares. Footnotes state the sales were undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses and that Pelizzon may be deemed a beneficial owner through his role at Squadron but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) had a large shareholder, Squadron Capital, LLC, file a notice of proposed sale of common stock under Rule 144. Squadron, identified as a 10% stockholder, plans to sell up to 700,000 shares of KIDS common stock through broker Stifel Nicolaus & Company Inc.
The filing lists an aggregate market value of approximately $18,361,000 for these shares and states there are 26,109,788 shares of common stock outstanding. Squadron notes that the shares to be sold represent about 10% of its holdings and that the sale is intended to provide additional capital for its other portfolio businesses.
The shares being sold were originally acquired from the issuer on 09/20/2022 through a purchase of 1,525,000 common shares, with consideration described as cash plus forgiveness of debt, with payment dated 08/15/2022. The notice is dated 08/24/2026.
OrthoPediatrics Corp. reported Q2 2026 net revenue of $70.5 million, up 15% from $61.1 million, with first‑half revenue rising 14% to $129.9 million. Growth was led by trauma and deformity products, where Q2 sales increased 26% to $52.6 million, while scoliosis Q2 revenue declined 9% to $16.9 million. Gross margin improved to 74% from 72% for both the quarter and year‑to‑date.
Q2 operating loss narrowed to $4.1 million from $10.7 million, but higher interest expense turned prior‑year other income into expense, leaving Q2 net loss essentially flat at $7.2 million (EPS $(0.30)). First‑half net loss was $17.9 million, or $(0.75) per share. At June 30, 2026, cash, restricted cash and short‑term investments totaled $47.9 million against total debt of $105.8 million, including a $51.0 million term loan and $50.0 million of 4.75% convertible notes due 2030. Net cash used in operating activities improved to $2.4 million from $14.6 million a year earlier. Management states that existing cash, expected cash flows and an undrawn $20.0 million delayed draw term loan under the Braidwell amendment are expected to support operations for more than 12 months.
OrthoPediatrics Corp., a company focused exclusively on pediatric orthopedics, presents an investor update highlighting a $6.2B global addressable market and a strategy centered on child-specific implants, a broad product portfolio, global sales coverage and extensive clinical education for pediatric orthopedic surgeons.
The company reports steady revenue expansion, with 2025 revenue of $236.3 million versus $204.7 million in 2024, and 2Q 2026 revenue of $70.5 million compared with $61.1 million in 2Q 2025. Despite growth, OrthoPediatrics continues to post net losses, including a 2025 diluted EPS of $(1.69).
Management provides 2026 guidance for revenue of $265.0–$269.0 million, Adjusted EBITDA of approximately $25.0 million and roughly breakeven free cash flow. As of June 30, 2026, the balance sheet shows $47.9 million in cash and short-term investments and $99.6 million of debt. The presentation also outlines a multi-year “super-cycle” of differentiated pediatric product launches and explains non-GAAP measures such as Adjusted EBITDA, adjusted diluted loss per share and free cash flow used in assessing operating performance.
OrthoPediatrics Corp. reported record second-quarter 2026 net revenue of $70.5 million, up 15% from $61.1 million a year earlier, driven by 26% growth in Trauma and Deformity products and 22% international revenue growth. U.S. revenue was $54.8 million and international revenue $15.7 million. Gross profit rose to $52.4 million with margin improving to 74% from 72%.
Adjusted EBITDA reached a record $6.8 million versus $4.1 million in 2025, while net loss was $7.2 million, or $0.30 per share, similar to the prior year. Free cash flow usage in the quarter improved to $3.1 million from $13.9 million. The company raised full-year 2026 revenue guidance to $265.0–$269.0 million, reiterated expected adjusted EBITDA of about $25.0 million, and continues to target breakeven free cash flow in 2026.
Integrated Core Strategies (US) LLC and related Millennium entities reported beneficial ownership of OrthoPediatrics Corp. common stock on a Schedule 13G/A. Integrated Core Strategies (US) LLC reports 811,042 shares, representing 3.2% of the common stock with shared voting and dispositive power only.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 816,830 shares, also equal to 3.2% of the class, with no sole voting or dispositive power. The filers state they collectively own 5 percent or less of the class and clarify that their control relationships do not, by themselves, constitute an admission of beneficial ownership. A joint filing agreement among the four reporting persons is included.
Pelizzon David R reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director David R. Pelizzon received an award of 11,436 shares of common stock on June 9, 2026. The shares were granted at no cost as a stock award, increasing his direct holdings to 44,384 common shares, including 17,959 restricted stock awards.
The filing also reports 6,901,764 common shares held indirectly through Squadron Capital LLC. As President and a member of Squadron’s Managing Committee, Pelizzon may be deemed a beneficial owner, but he expressly disclaims beneficial ownership except for his pecuniary interest.